Loading...
•
Dec 31, 2025
Myomo Q4 2025 Earnings Report
Myomo Q4 2025 Earnings Report
Key Takeaways
Myomo reported a 6% decrease in Q4 revenue to $11.4 million, primarily due to lower unit volume and average selling prices. Despite the quarterly decline, the company achieved record full-year revenue and is shifting its strategy toward recurring patient sources and O&P channels to improve margins and reduce customer acquisition costs in 2026.
Q4 revenue of $11.4 million decreased 6% year-over-year, though full-year revenue grew 26% to $40.9 million.
Recurring patient sources accounted for 42% of Q4 revenue, up significantly from 26% in the prior year quarter.
The company achieved a record 241 MyoPro authorizations and orders during the fourth quarter.
Gross margin for the quarter was 68.6%, a sequential improvement of 480 basis points from Q3 2025, despite a year-over-year decline.
Revenue by Segment
Forward Guidance
Myomo expects 2026 to be a transition year with a focus on recurring revenue and improved operating leverage.
Positive Outlook
- Full year 2026 revenue guidance of $43 million to $46 million.
- Targeting a 20% reduction in material costs by the second half of 2026.
- Operating expense growth expected to be half the rate of revenue growth.
- Plan to reduce negative free cash flow (cash burn) by approximately half compared to 2025.
- Increased emphasis on lower-cost customer acquisition through the MyoConnect program.
Challenges Ahead
- Q1 2026 revenue expected to be seasonally lower, between $9.0 million and $9.5 million.
- Transition year involves reducing dependence on traditional advertising-driven revenue.
- Ongoing dependence on external sources for financing operations.
- Revenue concentration risk remains with Medicare Part B patients.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...